A US jury awarded Nektar Therapeutics $90 million in its dispute with Eli Lilly over a fractured licensing deal tied to rezpegaldesleukin, according to reports from the US District Court. The decision found Lilly breached the implied covenant of good faith and fair dealing, though the damages were far lower than what Nektar sought. The ruling has immediate implications for how partners interpret collaboration obligations in complex co-development structures, particularly for biologics where development responsibilities and decision rights can be tightly intertwined. For both companies, the outcome becomes a new reference point for any future restructuring, negotiations, or settlement frameworks in CGT-adjacent and immunology partnerships.